RxDoctor Payments DataLook up a doctor →

Phillip Henderson, DO

Gastroenterology · Mobile, ALNPI 1144450792

Payments from drug & device makers

$461,537in general payments, 2019–2025

Across 592 payments — averaging $779.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$145K
  • Madrigal Pharmaceuticals$132K
  • AbbVie$111K
  • Intercept Pharmaceuticals, Inc.$53K
  • Novo Nordisk$19K
  • Takeda Pharmaceuticals U.S.A., Inc.$247
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$3,4231%
  • Speaking & faculty fees$372,78081%
  • Travel & lodging$72,45016%
  • Food & beverage$12,8383%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$461,537 in reported general payments places this provider in the 95th percentile of 225 gastroenterology providers in Alabama.

See all gastroenterology providers in Alabama

Medicare billing

Part B allowed, 2024
$67,786
Medicare patients
318
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin216$769,378
VemlidyTenofovir Alafenamide31$44,145
Everolimus32$31,876
Ursodiol161$24,793
LinzessLinaclotide35$23,166
OzempicSemaglutide15$16,535
Tenofovir Disoproxil Fumarate74$10,234
Mycophenolate Mofetil109$8,548
Tacrolimus155$8,070
Sucralfate25$7,783
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates83$5,303
Sirolimus26$5,022
Lactulose123$3,801
Azathioprine75$3,086
Nadolol49$2,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$60$769,378216 claims
GileadVemlidy$144,729$44,14531 claims
AbbVieLinzess$110,663$23,16635 claims
Novo NordiskOzempic$19,310$16,53515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 gastroenterology providers in Alabama.

Other gastroenterology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →